OrbusNeich continued its global row against medtech titan Boston Scientific (NYSE:BSX) even further, filing a patent infringement lawsuit in Ireland to join ones pending in Germany and the Netherlands.

Much like the prior lawsuits, the new complaint alleges that Boston Scientific’s Promus Element, Promus Element Plus, Taxus and other stents are infringing on a pair of OrbusNeich patents.

OrbusNeich is seeking damages for infringement as well as an injunction preventing Boston Scientific from manufacturing or selling the offending products in Ireland.

"The lawsuit in Ireland is a continuation of our efforts to protect and enforce our intellectual property rights," OrbusNeich chairman & CEO Al Novak said in prepared remarks. "We intend to vigorously pursue these efforts to prevent unlawful competitive practices and protect our unique technologies throughout the world."

The companies are fighting the same battle in the U.S., where a lawsuit filed in 2009 has been stayed pending review of the patents in question.

Last month OrbusNeich notched a European win in the long-running patent battle when the European Patent Office denied a bid by Boston Scientific and its Japanese ally Terumo Corp.(TYO:4543) to have the OrbusNeich’s patent overturned.